Infection with hiv-2

AIDS

Volumn 15, Issue SUPPL. 5, 2001, Pages

  Bock, P J ^a   Markovitz, D M ^a  

^a 5220 MSRB III ^*  (United States)

Author keywords

HIV 2

Indexed keywords

CD4 ANTIGEN; GAG PROTEIN; POL PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS RECEPTOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CLINICAL FEATURE; DISEASE COURSE; DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR EVOLUTION; NONHUMAN; OPPORTUNISTIC INFECTION; PORTUGAL; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T LYMPHOCYTE SUBPOPULATION; TRANSCRIPTION REGULATION;

EID: 0035663379     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200100005-00006     Document Type: Review

References (173)

1. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa
2. Molecular cloning and polymorphism of the human immune deficiency virus type 2
3. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa
4. Genome organization and transactivation of the human immunodeficiency virus type 2
5. Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses
6. An African primate lentivirus (SIVsm) closely related to HIV-2
7. Biologic features of HIV-2. An update
8. Slower heterosexual spread of HIV-2 than HIV-1
9. Reduced rate of disease development after HIV-2 infection as compared to HIV-1
10. Tracking the HIV epidemic: Current issues, future challenges
11. Surveillance for HIV-2 infection in blood donors - United States 1987-1989
12. Testing for antibodies to human immunodeficiency virus type 2 in the United States
13. Surveillance for HIV-2 in the United States: Update and recommendations for future surveillance
14. HIV-2-associated AIDS in the 1970s
15. HIV-2 in West Africa in 1966
16. Epidemiology and natural history of HIV-2
17. Infection with the human immunodeficiency virus type 2
18. Human immunodeficiency virus (HIV-2)
19. Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load
20. Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa
21. Prevalence and incidence of HIV-1, HIV-2, HTLV, and Treponema pallidum infections among police officers in Guinea-Bissau
22. HIV trends in African blood donors
23. Epidemiology and transmission of HIV-2 Why there is no HIV-2 pandemic
24. Update: HIV-2 infection among blood and plasma donors - United States June 1992-June 1995
25. The origins of the AIDS virus
26. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes
27. AIDS as a zoonosis: Scientific and public health implications
28. Antibodies to simian T-lymphotropic retrovirus type III in African green monkeys and recognition of STLV-III viral proteins by AIDS and related sera
29. Isolation of a simian immunodeficiency virus related to human immunodeficiency virus type 2 from a West African pet sooty mangabey
30. Human infection by genetically diverse SIVSM-related HIV-2 in West Africa
31. Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys)
32. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys
33. Variability of human immunodeficiency virus type 2 (HIV-2) infecting patients living in France
34. The phylogenetic history of immunodeficiency viruses
35. Induction of AIDS by simian immunodeficiency virus from an African green monkey: Species-specific variation in pathogenicity correlates with the extent of in vivo replication
36. Natural protection against HIV-1 infection provided by HIV-2
37. HIV-2 and natural protection against HIV-1 infection
38. Protection from HIV-1 infection by HIV-2
39. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: Significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection
40. Does HIV-2 protect against HIV-1 infection?
41. Does HIV-2 infection provide cross-protection against HIV-1 infection?
42. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, West Africa: No protection of HIV-2 against HIV-1 infection
43. Lack of protection against HIV-1 infection among women with HIV-2 infection
44. Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: A new approach to gene therapy of HIV-infection
45. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy
46. Inhibition of HIV-1 expression by HIV-2
47. Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades
48. Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity
49. In vitro correlates of HIV-2-mediated HIV-1 protection
50. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections
51. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection
52. HIV-2 antisera cross-neutralize HIV-1
53. An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV
54. Protection against human immunodeficlency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2
55. A minimally replicative HIV-2 live-virus vaccine protects M. nemestrina from disease after HIV-2(287) challenge
56. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques
57. Challenges in the development of an effective HIV vaccine: Current approaches and future directions
58. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses
59. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
60. Identification of a major coreceptor for primary isolates of HIV-1
61. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
62. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
63. Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains
64. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells
65. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4
66. CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2
67. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: Comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo
68. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion
69. A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4
70. Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2
71. Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein
72. Expression cloning of new receptors used by simian and human immunodeficiency viruses
73. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities
74. A CXC chemokine receptor, CXCR5/BLR1, is a novel and specific coreceptor for human immunodeficiency virus type 2
75. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage
76. Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function
77. Differential regulation of human immunodeficiency viruses (HIVs): A specific regulatory element in HIV-2 responds to stimulation of the T-cell antigen receptor
78. Dysregulation through the NF-kappaB enhancer and TATA box of the human immunodeficiency virus type 1 subtype E promoter
79. Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals
80. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer
81. Differential regulation of the human immunodeficiency virus type 2 enhancer in monocytes at various stages of differentiation
82. A novel Ets-related transcription factor, Elf-1, binds to human immunodeficiency virus type 2 regulatory elements that are required for inducible trans activation in T cells
83. Activation of the human immunodeficiency virus type 2 enhancer is dependent on purine box and kappa B regulatory elements
84. The peri-kappa B site mediates human immunodeficiency virus type 2 enhancer activation in monocytes but not in T cells
85. Identification of highly attenuated mutants of simian immunodeficiency virus
86. The role of upstream U3 sequences in the pathogenesis of simian immunodeficiency virus-induced AIDS in rhesus monkeys
87. Efficient transcription and replication of simian immunodeficiency virus in the absence of NFkappaB and Spl binding elements
88. The sequence and structure of the 3′ arm of the first stem-loop of the human immunodeficiency virus type 2 trans-activation responsive region mediate Tat-2 transactivation
89. Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4
90. New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM)
91. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2
92. HIV-1 auxiliary proteins: Making connections in a dying cell
93. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
94. The ins and outs of HIV Rev
95. The multifaceted role of HIV Nef
96. The numerous effector functions of Nef
97. HIV neff the mother of all evil?
98. Molecular biology of the human immunodeficiency virus accessory proteins
99. HIV accessory proteins: Leading roles for the supporting cast
100. Structural biology of HIV
101. Vpr-induced cell cycle arrest is conserved among primate lentiviruses
102. When accessories turn out to be essential
103. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release
104. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains
105. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules
106. Differential apoptosis effects of primate lentiviral Vpr and Vpx in mammalian cells
107. Vpx association with mature core structures of HIV-2
108. The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells
109. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: Mutational analysis of a primary HIV-1 isolate
110. HIV-1 replication in CD4+ T cell lines: The effects of adaptation on co-receptor use, tropism, and accessory gene function
111. Antibodies to the HIV type 2 core protein p26 and Vpx: Association with disease progression
112. A naturally immunogenic virion-associated protein specific for HIV-2 and SIV
113. Human immunodeficiency virus type 2 Vpx-Gag interaction
114. Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: Evidence of macrophage-dependent viral amplification
115. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM)
116. Progression to AIDS in the absence of a gene for vpr or vpx
117. Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal
118. Prospective comparison of mother-to-child transmission of HIV-1 and HIV2 in Abidjan, Ivory Coast
119. Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in West African female prostitutes
120. Risk factors for HIV-2 seropositivity among older people in Guinea-Bissau. A search for the early history of HIV-2 infection
121. Genetic characterization of viral quasispecies in blood and cervical secretions of HIV-1- and HIV-2-infected women
122. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambla Government/University College London Medical School working group on mother-child transmission of HIV
123. Vertical transmission of HIV-2
124. Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmission
125. Maternal HIV-1 and HIV-2 infection and child survival in The Gambia
126. HIV-2 in pregnancy: To treat or not to treat?
127. Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex Clinical and virological features in four patients
128. HIV-2 and HIV-1 AIDS cases in Senegal: Clinical patterns and immunological perturbations
129. Clinical, hematologic, and immunologic cross-sectional evaluation of individuals exposed to human immunodeficiency virus type-2 (HIV-2)
130. Clinical features, immunological changes and mortality in a cohort of HIV-2-infected individuals in Bissau, Guinea-Bissau
131. Long incubation period for HIV-2 infection
132. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: Low virus production in vivo
133. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2
134. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections
135. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
136. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
137. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
138. Characterization of long-term survivors of human immunodeficiency virus type 1 infection
139. Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8
140. 9-Year HIV-2-associated mortality in an urban community in Bissau, West Africa
141. Mortality among human immunodeficiency virus type 2-positive villagers in rural Guinea-Bissau is correlated with viral genotype
142. A community-based study of human immunodeficiency virus type 2 provirus load in rural village in West Africa
143. Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay
144. Proviral load and immune function in blood and lymph node during HIV-1 and HIV-2 infection
145. HIV-2 and the immune response
146. Analysis of lymphocyte cell death and apoptosis in HIV-2-infected patients
147. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: Correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution
148. AIDS following mother-to-child transmission of HIV-2
149. Getting to know HIV
150. HIV-2-associated AIDS and HIV-2 seroprevalence in Bissau, Guinea-Bissau
151. HIV-2-induced immunosuppression among asymptomatic West African prostitutes: Evidence that HIV-2 is pathogenic, but less so than HIV-1
152. The mortality and pathology of HIV infection in a West African city
153. Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast
154. Natural history and spectrum of disease in adults with HIV/AIDS in Africa
155. Retinal manifestations of HIV-1 and HIV-2 infections among hospital patients in The Gambia, West Africa
156. Identification of her-pesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
157. Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma
158. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae
159. The enigmas of Kaposi's sarcoma
160. HIV-1, HHV-8, and Kaposi's sarcoma
161. Human immunodeficiency virus type 2
162. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy
163. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy
164. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2
165. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2)
166. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance
167. HIV proteinase inhibitors
168. Update on antiretroviral therapy of HIV infection
169. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
170. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States
171. Prevention of mother-to-child transmission of HIV in developing countries: Recommendations for practice. The Ghent International Working Group on Mother-To-Child Transmission of HIV